exclusivity

(redirected from exclusivities)
Also found in: Medical.

ex·clu·sive

 (ĭk-sklo͞o′sĭv)
adj.
1. Excluding or tending to exclude: exclusive barriers.
2. Not allowing something else; incompatible: mutually exclusive conditions.
3. Not divided or shared with others: exclusive publishing rights.
4. Not accompanied by others; single or sole: your exclusive function.
5. Complete; undivided: gained their exclusive attention.
6. Not including the specified extremes or limits, but only the area between them: 10-14, exclusive; that is, 11, 12, and 13.
7. Excluding some or most, as from membership or participation: an exclusive club.
8. Catering to a wealthy clientele; expensive: exclusive shops.
9. Linguistics Relating to or being a first person plural pronoun that excludes the addressee, such as we in the sentence Pat and I are in town, so we can meet you for lunch.
n.
1. A news item initially released to only one publication or broadcaster.
2. An exclusive right or privilege, as to market a product.

ex·clu′sive·ly adv.
ex·clu′sive·ness, ex′clu·siv′i·ty (ĕk′sklo͞o-sĭv′ĭ-tē) n.

ex•clu•siv•i•ty

(ˌɛks kluˈsɪv ɪ ti)
n.
1. the state or quality of being exclusive; exclusiveness.
2. exclusive rights.
[1925–30]
Translations
exclusivitate

exclusivity

[ɪkskluːˈsɪvətɪ] Nexclusividad f

exclusivity

Mentioned in ?
References in periodicals archive ?
It takes the surprising step of limiting innovator exclusivities as part of deeming products to be licensed as biologics under Section 351 of the Public Health Service Act (PHSA).
As part of the settlement agreements, certain generic companies have licenses that will permit these companies to launch their generic versions of NAMENDA three months before the expiration of US Patent Number 5,061,703, including any extensions and/or pediatric exclusivities, or earlier in certain circumstances.
To avoid such a situation, the FDA has determined that, in cases involving blocking exclusivities, more than one genetic drug applicant may be entitled to shared exclusivity (i.
Central to each of these exclusivities is a public policy trade-off: a restriction on competition is provided in return for the development of a new drug product or new use of an existing product.